Use of parasites and extracellular vesicles obtained from the parasites for a cancer treatment is provided. The use of parasites and extracellular vesicles obtained from parasites is for using in a treatment of a cancer, and loading an active substance on exosomes by using a drug loading capacity of exosomes, and thus, by carrying a specific drug directly to target cancer cells without causing any side effect on healthy cells and to enhance a bioavailability of the specific drug, achieving a desired effect in a tumor specific target region. Particularly Leishmania infantum parasite is used as a source for the extracellular vesicles.

The current disclosure provides methods and compositions useful in preparing transformed and immortalized zebra and quagga mussel cells that function as disseminated neoplastic (DN) cells, as well as the cells produced thereby. Also provided are methods for using such mussel DNCs in cell culture, in vitro, and within live mussels in the lab or in the wild, to control mussel populations such as invasive zebra mussel or quagga mussel populations.

The present disclosure is directed to methods for the formation and production of renewable muscle and/or fat primary cell lines, immortalized cell lines, and stem cell lines from shrimp, prawn, crab, crayfish, and/or lobster species and the cell lines themselves as well as human and animal consumable meat products produced therefrom.

Provided a recombinant classical swine fever virus E2 protein comprising at least one mutation at the epitope specifically recognized by the 6B8 monoclonal antibody. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

The present invention relates to insect cell lines for the production of parvoviral gene therapy vectors. In particular the invention relates to stable insect cell lines with expression constructs for viral replicase proteins integrated into their genomes, which cell lines allow for high-yield, robust, and scalable production of heterologous parvoviral-related proteins and vectors.

The present invention provides a method of manufacturing a coral scaffold for use as a bone graft substitute. The method comprises growing coral in a growth medium having a carbonate hardness, dKH, of 10 or more; removing at least a portion of the coral from the growth medium; devitalising coral removed from the growth medium and sizing the devitalised coral to form the coral scaffold.

Described herein are compositions and methods to cryopreserve sporozoites. In some aspects, the method can include the step of placing harvested salivary glands containing sporozoites into an insect-based medium.

An insect culture maintenance system includes a sequence of open-ended cylindrical tubes [500, 502, 504, 506] joined pairwise alternately at their tops and bottoms using multiple dual-cap connectors. Each dual-capped connector has a channel from an inside of a first cap to an inside of a second cap. In use, connectors that cap the bottoms of the tubes [508, 512] are filled with insect food media [518, 520], while connectors that cap the tops of the tubes [510] are open. As a result of this design, adults pass from one tube to the next through the top dual-cap connectors, while larvae pass from one tube to the next through the bottom dual-cap connectors, resulting in propagation of subsequent generations of insects through the sequence of tubes.

Disclosed herein are compositions comprising recombinant adeno-associated virus (rAAV), as well as recombinant baculovirus systems and methods of using the same for producing and purifying such compositions. Also disclosed herein are assays for testing the titer and potency of such compositions.

The present disclosure provides culture or fermentation media including a biomass or derivative thereof of a hemoprotein-producing C.sub.1 metabolizing non-photosynthetic bacterium, methods of culturing cells or tissue with the culture or fermentation medium, and products produced by the culturing methods including food products, food ingredients, phytoprotective bacterial cell products, and other products of interest such as vitamins, fatty acids, amino acid, carotenoids, etc.